Overview
- Peer-reviewed results in BMC Medicine from Case Western Reserve University and University Hospitals detail robust anti-tumor effects in preclinical studies.
- The engineered CAR-T uses a ligand-based design to target two receptors for oncostatin M—OSMR and LIFR—addressing solid-tumor heterogeneity.
- Treatment reduced tumor burden in multiple mouse models, including models of disease that had spread to lungs and other organs.
- Activity was observed across all tested patient-derived osteosarcoma samples, including a treatment-resistant patient-derived xenograft model.
- Investigators plan to submit an IND and anticipate launching clinical trials within roughly two years, with human safety and efficacy still unproven.